MAZE vs PVLA
MAZE: Maze Therapeutics leverages human genetics data and its Compass platform to discover and develop novel therapeutic candidates across multiple disease indications. PVLA: A clinical-stage biopharmaceutical company developing proprietary therapeutics for rare skin diseases and vascular malformations following the merger of Pieris Pharmaceuticals and Legacy Palvella.
Side-by-side fundamentals
| Metric | MAZE | PVLA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $28.49 | $142.18 | |
| Market cap as of 2026-07-23 | $1.6B | $2.0B | |
| Net margin as of 2026-07-23 | +11.0% | -39.7% | MAZE higher |
| Operating margin as of 2026-07-23 | +34.4% | -47.8% | MAZE higher |
| ROE as of 2026-07-23 | -36.6% | -56.9% | MAZE higher |
| ROA as of 2026-07-23 | -31.8% | -42.5% | MAZE higher |
| Debt / equity as of 2026-07-23 | 0.11 | 0.09 | PVLA lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -97.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +13.4% | |
| Beta as of 2026-07-23 | 1.10 | -0.20 | |
| 1-year return as of 2026-07-22 close | +75.9% | +294.9% | PVLA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.